

# **Social prescribing for People Living with Dementia (PLWD) and their carers: what works, for whom, under what circumstances, and why: Protocol for a complex intervention systematic review**

## **Authors:**

**Jessica Marshall**, *University of East Anglia*, [j.marshall@uea.ac.uk](mailto:j.marshall@uea.ac.uk)

ORCID ID: 0009-0001-8234-6077

**Dr Evie Papavasiliou**, *University of Leeds*, [e.papavasiliou@leeds.ac.uk](mailto:e.papavasiliou@leeds.ac.uk)

ORCID ID: 0000-0002-6504-515X

**Prof. Chris Fox**, *University of Exeter*, [christopher.fox@exeter.ac.uk](mailto:christopher.fox@exeter.ac.uk)

ORCID ID: 0000-0001-9480-5704

**Matthew Hawkes**, *University of East Anglia*, [m.hawkes@uea.ac.uk](mailto:m.hawkes@uea.ac.uk)

**Anne Irvine**, *University of East Anglia*, [anne.irvine10@outlook.com](mailto:anne.irvine10@outlook.com)

**Prof. Esme Moniz-Cook**, *University of Hull*, [e.d.moniz-cook@hull.ac.uk](mailto:e.d.moniz-cook@hull.ac.uk)

ORCID ID: 0000-0002-7232-4632

**Aimee Pick**, *Newcastle University*, [aimee.pick@newcastle.ac.uk](mailto:aimee.pick@newcastle.ac.uk)

ORCID ID: 0009-0008-6361-2297

**Dr Marie Polley**, *Meaningful Measures Ltd*, [marie@meaningfulmeasures.co.uk](mailto:marie@meaningfulmeasures.co.uk)

ORCID ID: 0000-0003-3823-5668

**Prof. Joanne Reeve**, *Hull York Medical School*, [joanne.reeve@hyms.ac.uk](mailto:joanne.reeve@hyms.ac.uk)

ORCID ID: 0000-0002-3184-7955

**Prof. Dame Louise Robinson**, *Newcastle University*,

[a.l.robinson@newcastle.ac.uk](mailto:a.l.robinson@newcastle.ac.uk)

ORCID ID: 0000-0003-0209-2503

**George Rook**, *University of East Anglia*, [georgerook51@gmail.com](mailto:georgerook51@gmail.com)

**Dr Euan Sadler**, *University of Southampton*, [e.a.sadler@soton.ac.uk](mailto:e.a.sadler@soton.ac.uk)

ORCID: 0000-0003-3827-224X

**Dr Emma Wolverson**, University of Hull, [e.wolverson@hull.ac.uk](mailto:e.wolverson@hull.ac.uk)

ORCID ID: 0000-0002-5789-7862

**Dr Sarah Walker**, University of Exeter, [s.walker@exeter.ac.uk](mailto:s.walker@exeter.ac.uk)

ORCID ID: 0000-0003-4201-1093

**Dr Jane Cross**, University of East Anglia, [j.cross@uea.ac.uk](mailto:j.cross@uea.ac.uk)

ORCID ID: 0000-0002-7003-1916

On behalf of the SPLENDID Collaboration

Prof. Chris Fox, Dr Jane Cross, Prof. Louise Allan, Prof. Anthony Avery, Dr Katherine Bradbury, Anne Irvine, Jessica Marshall, Prof. Antonieta Medina-Lara, Prof. Esme Moniz-Cook, Nia Morrish, Prof. Martin Orrell, Dr Evie Papavasiliou, Aimee Pick, Prof. Fiona Poland, Dr Marie Polley, Dr Amy Rathbone, Prof. Joanne Reeve, Prof. Dame Louise Robinson, George Rook, Dr Euan Sadler, Dr Kritika Samsi, Prof. Lee Shepstone, Dr Sarah Walker, Dr Emma Wolverson

**Word Count: 3153**

#### **CORRESPONDING AUTHOR**

Dr Jane Cross

Faculty of Medicine and Health Sciences

University of East Anglia

Norwich Research Park

NR4 7TJ

[j.cross@uea.ac.uk](mailto:j.cross@uea.ac.uk)

University of East Anglia

## **ABSTRACT:**

**Introduction:** Dementia is a complex medical condition that poses significant challenges to healthcare systems and support services. . People living with dementia (PLWD) and their carers experience complex needs often exacerbated by social isolation and challenges in accessing support. Social prescribing (SP) seeks to enable PLWD and their carers to access community and voluntary sector resources to support them address such needs. Existing research, however, does not describe what SP interventions are currently in place in dementia care. Little is known about the needs these interventions are designed to address, the reasons that lead PLWD and their carers to participate in them, their effectiveness, and the extent to which they could increase positive health outcomes if adopted and how.

**Methods and Analysis:** A complex intervention systematic review of SP for PLWD and/or their carers will be conducted using an iterative logic model approach. Six electronic (MEDLINE, EMBASE, PsycINFO, CINAHL, Scopus, and Cochrane / CENTRAL) and two grey literature databases (ETHOS and CORE) were searched for publications between 1<sup>st</sup> January 2003 to June 2023, supplemented by handsearching of reference lists of included studies. Study selection, data extraction, and risk of bias assessment, using Gough's Weight of Evidence Framework, will be independently performed by two reviewers. A narrative approach will be employed to synthesise and report quantitative and qualitative data. Reporting will be informed by the Preferred Reporting Items for Systematic Review and Meta-Analysis Complex Interventions (PRISMA-CI) extension statement and checklist.

**Ethics and Dissemination:** No ethical approval is required due to this systematic review operating only with secondary sources. Findings will be disseminated through peer-reviewed publications, conference presentations and meetings with key stakeholders including healthcare professionals, patient and carer groups, community organisations (e.g., the Social Prescribing Network, and the Evidence Collaborative at the National Academy for Social Prescribing/NASP), policymakers, and funding bodies.

**Registration Details:** PROSPERO registration number CRD42023428625, 16th June 2023.

## **ARTICLE SUMMARY**

### **Strengths and Limitations of this Study**

This will be the first complex intervention systematic review to synthesise evidence on SP interventions in dementia care.

- This will be the first protocol using complex intervention systematic review methodology to report current social prescribing practice in dementia care.
- Logic modelling will be used to visualise the complexity of social prescribing for people living with dementia and their carers.
- The quality and relevance of findings will be strengthened by the contributions of the SPLENDID Work Package 1 Expert and the Patient & Public Involvement Advisory Groups involved in this study.
- This review may be confined by empirical evidence being scarce or heterogenous.
- Included studies were limited to those carried out within the United Kingdom and reported in the English Language due to the variation in coverage and delivery of social prescribing.

**KEYWORDS:**

Social prescribing, dementia care, health services research, primary care, social and health services,

**INTRODUCTION**

Dementia is a complex medical condition that poses significant challenges to healthcare systems and support services, affecting millions of people worldwide. In the UK, there are an estimated 944,000 people living with dementia [1], predicted to rise to over 1.1 million by 2030 [2]. People living with dementia (PLWD) and their carers experience multifaceted, complex needs (medical, emotional, social, financial, and practical) often exacerbated by social isolation and challenges in accessing support. Inability to consistently meet these needs in a timely manner can result in poorer health outcomes and quality of life [3]. Whilst a dementia diagnosis offered as early as possible is thought to mobilise support for PLWD, access to post-diagnostic care has been a challenge for people with dementia and their families [4]. This leads to high levels of stress, and distress when stress becomes unresolved [5].

Wider conceptualisation of health evidence in primary care and public health has advocated for care built on an understanding of wider social determinants of health [6]. One recent articulation is the concept of social health that focuses on three key dimensions (personal, disease-related, and social and physical environment influencing factors) [7-8], based on which, social prescribing interventions to counteract social isolation and disengagement for PLWD are built [9]. Social prescribing seeks to enable people with unmet complex needs to access community and voluntary sector resources to support them address their needs using non-biomedical approaches [10] which, in association with optimising social health, could improve the quality of daily living for PLWD and their carers. The diversity of social prescribing interventions offered (psycho-social, psychological, arts-based, and educational), the variability in outcome measures assessed, and the wide range of assessment instruments used indicate the complex nature of this non-pharmacological approach in dementia care [7].

Until recently, there was no standard definition of social prescribing, however, a Delphi study in 2022 [11] proposes both conceptual and operational definitions. For the purposes of this review, the conceptual definition will be adopted where social prescribing is defined as “a means for trusted individuals in clinical and community settings to identify that a person has non-medical, health-related social needs and to subsequently connect them to non-clinical supports and services within the

community by co-producing a social prescription – a non-medical prescription, to improve health and wellbeing and to strengthen community connections.” [11 p.9]. This internationally accepted definition clearly outlines the diverse structural components of social prescribing and signifies the complex and multi-dimensional nature of the intervention.

Existing research does not describe what social prescribing interventions are currently in place for PLWD and/or their carers, and while quality of life has been shown to improve and extend through creative and social engagement, the mechanisms and process by which this can be achieved through social prescribing have not been explored [12]. Moreover, evidence on the needs that social prescribing is designed to address and the extent to which social prescribing interventions have been effective for PLWD and their carers is limited and heterogeneous making it difficult for conclusions to be drawn [13]. Little is known about the uptake of social prescribing interventions by PLWD and/or their carers, the reasons (circumstances) that lead them to participate in such interventions, and the extent to which social prescribing interventions could potentially increase positive health outcomes if adopted and how [13]. To date there is no systematic review of social prescribing for PLWD and/or their carers (e.g., family, friends, neighbours) to address these knowledge gaps.

This systematic review is designed to identify, describe, and explore the mechanisms, processes, and circumstances by which PLWD and/or their carers participate in social prescribing interventions. The research questions are:

1. What social prescribing interventions are currently available for PLWD and/or their carers in the UK?
2. Which PLWD and/or their carers are social prescribing interventions being delivered to?
3. What are the mechanisms (incl. services and agents) by which social prescribing interventions for PLWD and/or their carers are being instigated?
4. What are the processes through which PLWD and/or their carers receive social prescribing interventions?
5. For what reasons/circumstances do PLWD and/or their carers participate in social prescribing interventions?
6. What are the effects of social prescribing on (i) PLWD and/or their carers and (ii) dementia related healthcare and how are these measured?

This review has been designed as a complex intervention systematic review in accordance with a series of articles providing guidance and tools for reviews of complex interventions published by the Agency for Healthcare Research and Quality (AHRQ) [14-20]. Focusing on uncovering and mapping the

complexity of social prescribing in dementia care, logic modelling [15-16] will be employed to highlight multiple interacting components, causal relationships, non-linear pathways, variability in content, context, and mode of delivery, as well as the unpredictability of impact and outcomes [21] of social prescribing interventions for PLWD and/or their carers.

## **METHODOLOGY**

### **Paradigm**

Logic modelling is a theory-based methodological paradigm, established and widely endorsed in programme evaluation research [22], acting as a tool to illustrate and understand complexity [23]. Usually described as graphic representations of a system, or an intervention in this case, logic models, can be used to depict core intervention components, expected outcomes and the complex pathways through which these are connected. They can also be used to recognise the influence of contextual and implementation factors, explain causal relationships, describe any implicit or explicit theory of change [23] and identify gaps in existing knowledge [24]. Using a logic model is useful for planning, implementing, and evaluating interventions, but also for making transparent assumptions and results more accessible to a wide range of key stakeholders [25].

The role of logic models in evidence synthesis has been gaining attention, increasingly adopted in systematic reviewing, contributing both conceptually and analytically to most stages of the review process. Their ability to conceptualise, map, and explain complexity when systematically gathering, integrating, and interpreting evidence from studies of complex interventions [22] makes logic modelling the most appropriate paradigm to use in this complex intervention systematic review.

### **Approach**

Considering the value that logic models can add to the different stages of the systematic review process [26], three main approaches to logic modelling can be identified i.e., a priori, staged, and iterative [26]. In the former, the logic model is constructed at protocol stage and finalised before any data is collected, not undergoing any further changes during the review process [22]. In the staged and iterative approach, the logic model is continuously revised, modified, and adapted during the data collection process [25-26]. The decision of which approach to use is informed by the scope, aims, and objectives of the systematic review [26].

In this complex intervention systematic review, an iterative approach to logic modelling will be utilised whereby the initial logic model will go through various modifications as new data and knowledge is

gained through the review process. The initial logic model will act as a guide to give 'an idea' of the key interacting components of the intervention.

Adaptation and modification of the initial logic model will continue throughout the review process as new insights emerge, which may identify new components, interrelationships between components, move existing components to more appropriate positions, or add scope to existing components. Finally, for the purposes of this complex intervention systematic review, the logic model will be revisited at the point of data extraction, data analysis, and prior to dissemination, with clearly labelled versions of the logic model detailing how, and based on what information, changes have been made.

### **Type**

Within each of the three approaches to logic modelling, two types of models have been identified: system-based and process-oriented logic models. System-based logic models represent the system in which interactions occur but are predominantly static in the sense that, while interactions are identified, they are not explored in further detail [25]. System-based models focus on depicting the complexity of the components of the intervention rather than their interaction. In contrast, process-oriented logic models graphically represent the causal pathways leading from intervention to outcomes [25] concentrating more on the key relationships embodied and their interaction [15].

Considering the aims of this review are to identify, illustrate, understand, and explain the complexity of social prescribing as an intervention for PLWD and/or their carers, a process-orientated model will be utilised.

### **Development of Initial Logic Model**

The initial process-oriented logic model will act as a guide for this complex intervention systematic review and was developed in the following six steps:

1. A model template including the target domains of the review (participants, intervention, outcomes, context, and implementation) was identified as a starting point to facilitate the development of an initial logic model [25].
2. This was shared with the team of multi-disciplinary experts involved in the review to initiate brainstorming and conceptualisation. Through discussion and consensus, the target domains of the model were populated while literature searches revealed several relevant published frameworks, aspects of which were used to further populate some of the domains. In terms of context and implementation, relevant aspects were derived from the Context and Implementation of Complex Interventions (CICI) Framework, a framework that consists of eight domains pertaining to context (i.e., setting, geographical, epidemiological, socio-cultural,

socioeconomic, ethical, legal, and political) and four domains pertaining to implementation (i.e., provider, organisation and structure, funding, and policy) [27]. Additionally, working definitions for all target domains were created by the review team and mapped onto the initial logic model for clarity.

3. An initial system-based logic model was designed to represent the complexities of the different components of the intervention under review. To turn this into a process-oriented logic model, representing how the intervention could produce change, arrows were used to indicate causal relationships (pathways) between the different components and their interaction, drawing upon the intervention Complexity Assessment Tool for Systematic Reviews (iCAT\_SR) [28]. This is a tool designed to assist reviewers in categorising, visually mapping, and better understanding intervention complexity using a typology that will be then used to support data extraction, analysis, and interpretation.
4. This logic model was considered by the SPLENDID Patient and Public Involvement (PPI) Advisory Group, to ensure that different perspectives were represented, and then refined based on the suggestions received.
5. The revised model was presented to the SPLENDID Work Package 1 Expert Advisory Group (researchers from a wide range of backgrounds including medicine, nursing, psychology, and sociology) for further feedback.
6. The final version of the initial logic model was approved by the review team (Figure 1).

## **Application**

The initial logic model, and its subsequent iterations, will be used as a model for data extraction, data analysis, and dissemination.

## **METHODS**

This protocol has been produced in line with the AHRQ series on complex intervention systematic review papers [14-20]. This review was registered with the International Register of Systematic Reviews ([PROSPERO](#)) on 16<sup>th</sup> June 2023 [CRD42023428625] and will be reported following the Preferred Reporting Items for Systematic Review and Meta-Analysis Complex Interventions (PRISMA-CI) extension statement and checklist [14-20].

Any subsequent modifications to the protocol will be recorded on PROSPERO and published in the findings of the review.



## **Eligibility Criteria**

The PICOTS (Population, Intervention, Context, Outcomes, Timing and Setting) framework was used to define and develop a list of inclusion and exclusion criteria (Table 1). PICOTS is an adaptation of the traditional PICO framework developed to map potential sources of complexity that can arise in a complex intervention systematic review, to which the addition of Timing and Setting captures dimensions of complexity relating to contextual factors [15].

PICOTS	Inclusion	Exclusion
Population	<p><i>Person living with dementia:</i></p> <ul style="list-style-type: none"> <li>• Anyone of any age, sex, ethnicity, and socio-economic status living with diagnosed dementia (of any subtype or stage).</li> <li>• Living in the community (residential care homes included), either independently or supported by others.</li> </ul> <p><i>Carers:</i></p> <ul style="list-style-type: none"> <li>• Of any age, sex, ethnicity, and socio-economic status.</li> <li>• Providing unpaid care help or support to a family member, partner or friend living with diagnosed dementia (of any subtype or stage) but can be receiving a carer's allowance.</li> </ul>	<p><i>Person living with dementia:</i></p> <ul style="list-style-type: none"> <li>• Not having a formal dementia diagnosis.</li> <li>• Living in a nursing home, a hospice or receiving inpatient or end of life care.</li> </ul> <p><i>Carers:</i></p> <ul style="list-style-type: none"> <li>• Anyone providing care to PLWD not having a formal dementia diagnosis.</li> <li>• Anyone providing paid care, help or support to PLWD (of any subtype or stage).</li> </ul>
Intervention	<p><i>Social prescribing (defined as): "a means for trusted individuals in clinical and community settings to identify that a person has non-medical, health related social needs and to subsequently connect them to non-clinical supports and services within the community by co-producing a social prescription – a non-medical prescription, to improve health and wellbeing and to strengthen community connections.[11 p.9]"</i></p> <p><b>Any non-medical interventions</b> (activities, groups, or services within the community that meet the practical, social, and emotional needs that affect health and wellbeing of patients living with dementia and/or their carers).</p> <p>run by</p> <p><b>Any voluntary or community sector organisations</b> (either community based or virtual)</p> <p>accessed through</p> <p><b>Any referral route</b> (such as primary care (GPs), charity, community interest group, local authority, self-referral, carer-referral but not limited to).</p> <p>via a</p> <p><b>Connector</b> (a trusted individual in a clinical or community setting involved in the delivery of social prescribing services)</p>	<ul style="list-style-type: none"> <li>• Any medical interventions (e.g., pharmacological).</li> <li>• Any non-medical interventions accessed without a connector being involved and no personalised co-produced care plan used.</li> </ul>

	through a  <b>Personalised co-produced care plan</b> (a verbal or written holistic, person-centred adaptive plan to address non-medical health related needs based on 'what matters' to a person)	
Context	<i>Published output:</i> <ul style="list-style-type: none"> <li>• Focusing on UK healthcare</li> <li>• Papers of any empirical design</li> <li>• Grey literature (reports)</li> <li>• January 2003-October 2023</li> </ul>	<i>Published output:</i> <ul style="list-style-type: none"> <li>• Focusing on International healthcare</li> <li>• Reviews</li> <li>• Case studies</li> <li>• Editorials</li> <li>• News</li> <li>• Conference abstracts &amp; proceedings</li> </ul>
Outcomes	Any quantitative (e.g., scores of psychometric instruments and/or other standardised measures) or qualitative (perceptions, thoughts, experiences) individual (health and non-health) and systemic outcomes, including proxy perspectives (see Figure 1).	No restriction
Timing	No time restriction	No time restriction
Setting	Community based living anywhere in the UK.	PLWD living in a nursing home, a hospice or receiving inpatient or end of life care.

Table 1. PICOTS table

## **Information Sources**

### *Electronic Searches*

Comprehensive systematic literature searches were performed in June 2023 in collaboration with an information specialist on the following databases: MEDLINE [Ovid], EMBASE [Ovid], PsycINFO [EBSCO], CINAHL [EBSCO], Scopus [Elsevier], and Cochrane / CENTRAL [Cochrane Library], from 1st January 2003 to June 2023; hand searching of reference lists continued throughout 2023. This timeframe was selected to account for all research conducted in the past twenty years, considering that, while social prescribing emerged as a concept in the late 1990s, the practice gained prominence in the early 2000s through pilot programs and initiatives in various parts of the United Kingdom (UK). Grey literature will be searched via EThOS and CORE databases. Database searches will be supplemented by hand searching of relevant grey literature including web archives of charities and government websites, as well as reference lists and citations of included studies. The search strategy will include text words and database-specific subject headings relating to each of the following areas: 'dementia', 'social prescribing', 'assessment', 'referral', 'link worker', and the 'UK' combined and tailored to the relevant database. The search strategy will be limited to studies conducted in the UK, due to the variation in coverage and delivery of social prescribing. Only studies reported in the English language will be included.

## **Data Collection and Analysis**

### *Study Selection*

Once the searches have been completed all studies identified will be extracted and imported to EndNote 20 for deduplication. Unique citations will be imported to Rayyan [29], the Intelligent Systematic Review Software, for screening. Title and abstracts will be independently screened against inclusion/exclusion criteria by two members of the review team. Full texts of potentially eligible papers identified during title and abstract screening will be independently assessed by at least two reviewers. Any discrepancies will be resolved through consensus-based decisions or, if necessary, in consultation with a third reviewer.

### *Assessment of Risk of Bias*

Gough's Weight of Evidence [30], a framework for the appraisal of the quality and relevance of evidence, applicable to both quantitative and qualitative papers, will be used to identify any risk of bias in the included studies by assessing study quality and relevance. Any disagreements of scores in

paper reviewing and assessment will be resolved through consensus-based decisions and in consultation with a third reviewer, where necessary.

#### *Data Extraction and Management*

The initial process-based logic model will be used to guide data extraction. A visual map of extracted information (using an Excel spreadsheet), coded under different domains of the model, based on the research questions addressed, will be constructed, and used to explore and account for the mechanisms, processes, and circumstances by which PLWD and/or their carers participate in social prescribing interventions.

Information to be extracted will include:

- i. participants (i.e., PLWD, family/carers, and providers) involved in the intervention,
- ii. mechanisms of intervention delivery,
- iii. implementation data (processes of intervention delivery),
- iv. multi-level contextual factors that influence implementation, intervention mechanisms and outcome, and
- v. outcome measures from the intervention

To ensure consistency and minimise bias of data extraction, 10% of included papers will be independently assessed by at least two members of the review team. The initial logic model will be reviewed at this stage and updated as necessary. Following that, data extraction for all included papers will continue to be carried out by at least two reviewers. The review team will meet regularly to discuss and resolve any differences in data extraction through discussion and consensus.

#### *Data Synthesis*

Due to the complexity of the topic addressed, heterogeneity of evidence identified is anticipated. Findings will, therefore, be integrated using narrative synthesis [31]. This approach was selected for its potential to synthesise heterogeneous and complex evidence in a rigorous and replicable way. Findings will be conceptually triangulated using the initial process-based logic model as a guide to construct groupings of evidence that are conceptually similar and identify and explore the relationships between these groupings. The SPLENDID PPI and SPLENDID Work Package 1 Expert Advisory Group will regularly offer guidance on data synthesis, mapping, and interpretation to ensure pertinent issues are identified and addressed.

#### *Analysis of subgroups or subsets*

Data permitting, subgroup analysis will be performed. It is not possible to specify the groups in advance.

### **SPLENDID Patient and Public Involvement (PPI) Group & SPLENDID Work Package 1 Expert Advisory Group**

#### *Patient and Public Involvement Statement*

The SPLENDID Patient and Public Involvement (PPI) and the SPLENDID Work Package 1 Expert Advisory Groups will be consulted at various stages of the review. Thus far, the groups have contributed to refining the review questions and the initial logic model by reviewing their relevance in the context of their own personal and professional experience. Any pertinent issues identified relating to contextual factors, implementation challenges, and outcomes, for which revisions were required, were considered, and revised accordingly. The groups will reconvene at the data synthesis stage to offer guidance to assess the preliminary themes identified and review their relevance. A final meeting will take place towards the end of the review for the groups to review and assess the reporting of findings and provide guidance on dissemination plans.

## **ETHICS AND DISSEMINATION**

### **Ethical Considerations**

This is a systematic review that strictly operates with secondary sources of data openly accessible in the public domain; therefore, no ethical approval or consent will be required.

### **Dissemination Plan**

To achieve widespread dissemination of the findings of this review, the following activities have been put in place: i. publishing in open access, peer-reviewed journals,

ii. presenting at relevant national and international conferences and other events, and

iii. organising dissemination meetings with key stakeholders such as health care professionals, patient and carer groups, community organisations (e.g., the Social Prescribing Network, and the Evidence Collaborative at the National Academy for Social Prescribing/NASP), policymakers, and funding bodies.

### **ACKNOWLEDGMENTS**

The authors would like to give special thanks to the SPLENDID Patient and Public Involvement Advisory Group, the SPLENDID Work Package 1 Expert Advisory Group, and the members of the SPLENDID Collaboration for their support and contribution to this work. We would also like to thank our charity partners TIDE and DEEP, and the Norwich Clinical Trials Unit, for their support.

The contract for this research is held by the Norfolk and Waveney Integrated Care Board (NWICB) and it is supported by the National Institute for Health and Care Research (NIHR) Applied Research Collaborations of the East of England, Wessex, and South West Peninsula. The views expressed in this publication are those of the authors and not necessarily those of the NWICB, the National Institute for Health and Care Research or the Department of Health and Social Care.

**AUTHORS' CONTRIBUTIONS.** Funding acquisition: JC and CF; Conceptualisation: JM, EP, SW and JC; Methodology: JM, EP, SW JC; Development of the logic model: JM, EP, CF, AI, EMC, AP, MP, JR, LR, GR, ES, EW, SW, JC; SPLENDID PPI Group: AI, GR; SPLENDID Work Package 1 Expert Advisory Group: CF, EMC, MP, JR, ES; Development of search strategy: JM, MH, EP; Writing – original draft preparation: JM, EP, SW, JC; Have reviewed and edited the protocol: JM, EP, CF, MH, AI, EMC, AP, MP, JR, LR, GR, ES, EW, SW, JC; Have approved submission(s): JM, EP, CF, MH, AI, EMC, AP, MP, JR, LR, GR, ES, EW, SW, JC.

## **FUNDING**

This study/project is funded by the NIHR Programme Grants for Applied Research [NIHR203280]. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

## **COMPETING INTERESTS**

Minor competing interest declared by co-author (EMC) regarding salary costs from the sponsor funded by the NIHR.

Figure 1. Initial Logic Model and complex terminology definitions

## **GLOSSARY OF TERMS & DEFINITIONS\*:**

1. *Dementia: a diagnosed syndrome related to cognitive and behavioural decline which over time affects memory, problem solving, language, mood, motivation, and behaviour to such an extent that it interferes with a person's daily life and activities.*
2. *Carers of PLWD: Anyone of any age who provides unpaid care, help or support to a family member, partner or friend who needs help because they have a dementia diagnosis.*
3. *Social Prescribing: a means for trusted individuals in clinical and community settings to identify that a person has non-medical, health related social needs and to subsequently connect them to non-clinical supports and services within the community by co-producing a social*

*prescription – a non-medical prescription, to improve health and wellbeing and to strengthen community connections [11 p.9].*

4. *Connector: A trusted individual in a clinical or community setting involved in the delivery of social prescribing services, who empowers a person through holistic support and a personalised co-produced care plan to connect them to voluntary and community sector organisations.*
5. *Non-medical intervention: A non-clinical approach, activity, opportunity, or support scheme.*
6. *Delivery: Intervention delivery describes the ‘how’ (delivery mechanisms), ‘who’ (delivery agents), ‘where’ (setting) of the intervention [25].*
7. *Personalised co-produced care plan: A verbal or written holistic, person-centred adaptive plan based on ‘what matters’ to a person. It is produced in equal partnership with a trusted individual in a clinical or community setting to address non-medical health related needs.*
8. *Voluntary and community sector organisations: A not for profit, non-clinical community asset or scheme that offers people in-person or remote services, activities, opportunities, or support.*
9. *Community based living: Living primarily in the community, either independently or supported by others, including in a residential care home, but not in a nursing home, a hospice or receiving inpatient or end of life care.*
10. *Wellbeing: Exists in two dimensions. Subjective wellbeing relates to how people feel and how they function on a personal level in relations to their financial, health, social, personal, and local environment. Objective wellbeing relates to objective measures of an individual’s being and assumptions about basic human needs and rights.*
11. *Quality of life: A multidimensional measure of an individual’s health in terms of (but not limited to) their physical, psychological, social, personal, and environmental state.*

\*Working definitions of terms for which inconsistency and/or ambiguity persists in the current literature were specifically developed drawing on stakeholder conversations, clinical, peer reviewed and grey literature, being adapted to fit the aims of this CISR.



## REFERENCES

1. Dementia Statistics Hub. Statistics about dementia [online]. 2022. Available at: <https://dementiastatistics.org/about-dementia/> (accessed 11<sup>th</sup> September 2023)
2. Dementia Statistics Hub. Prevalence and incidence [online]. Dementia Statistics Hub. Available at: <https://dementiastatistics.org/about-dementia/prevalence-and-incidence/> (accessed 11<sup>th</sup> September 2023)
3. Frost R, Walters K, Wilcock J, et al. Mapping post-diagnostic dementia care in England: an e-survey. *Journal of Integrated Care*. 2020; 30;29(1):22–36
4. van Horik JO, Collins R, Martyr A, et al. Limited receipt of support services among people with mild-to-moderate dementia: findings from the IDEAL cohort. *International Journal of Geriatric Psychiatry*. 2022; 37(3):1–8.
5. Kinnaird L. Responding to Stress and Distress in Dementia, Alzheimer Scotland [online]. 2018. Available at: <https://www.alzscot.org/sites/default/files/2019-11/Understanding%20stress%20and%20distress%20in%20dementia.pdf> (accessed 11<sup>th</sup> September 2023)
6. World Health Organisation. Social determinants of health [online]. 2023. Available at: [https://www.who.int/health-topics/social-determinants-of-health#tab=tab\\_1](https://www.who.int/health-topics/social-determinants-of-health#tab=tab_1) (accessed 11<sup>th</sup> September 2023)
7. Reilly ST, Harding AJE, Morbey H, et al. What is important to people with dementia living at home? A set of core outcome items for use in the evaluation of non-pharmacological community-based health and social care interventions. *Age and Ageing*. 2020; 17;49(4):664–71.
8. Dröes RM, Chattat R, Diaz A, et al. Social health and dementia: a European consensus on the operationalization of the concept and directions for research and practice. *Aging & Mental Health*. 2016; 21;21(1):4–17.
9. Alzheimer's Society. Personalised Care, Social Prescribing, Assessment and Improvement [online]. 2023. Available from: <https://www.alzheimers.org.uk/dementia-professionals/dementia-experience-toolkit/need-measure-experience/personalised-care-social-prescribing> (accessed 11<sup>th</sup> September 2023)
10. Tierney S, Wong G, Roberts N, et al. Supporting social prescribing in primary care by linking people to local assets: a realist review. *BMC Medicine*. 2020; 13;18(1). doi: 10.1186/s12916-020-1510-7
11. Muhl C, Mulligan K, Bayoumi I, et al. Establishing Internationally Accepted Conceptual and Operational Definitions of Social Prescribing Through Expert Consensus: A Delphi Study. *BMJ Open*. 2023. 13:e070184. doi: 10.1136/bmjopen-2022-070184
12. Gallacher J, Burns A. Social prescribing for dementia. *The Lancet Neurology*. 2021;20(9):707–8.
13. Baker K, Irving A. Co-producing Approaches to the Management of Dementia through Social Prescribing. *Social Policy & Administration*. 2015 16;50(3):379–97.

14. Guise JM, Chang C, Butler M, et al. AHRQ series on complex intervention systematic reviews—paper 1: an introduction to a series of articles that provide guidance and tools for reviews of complex interventions. *Journal of Clinical Epidemiology*. 2017;90:6–10.
15. Kelly MP, Noyes J, Kane RL, et al. AHRQ series on complex intervention systematic reviews—paper 2: defining complexity, formulating scope, and questions. *Journal of Clinical Epidemiology*. 2017;90:11–8.
16. Butler M, Epstein RA, Totten A, et al. AHRQ series on complex intervention systematic reviews—paper 3: adapting frameworks to develop protocols. *Journal of Clinical Epidemiology*. 2017;90:19–27.
17. Viswanathan M, McPheeters ML, Murad MH, et al. AHRQ series on complex intervention systematic reviews—paper 4: selecting analytic approaches. *Journal of Clinical Epidemiology*. 2017;1;90:28–36.
18. Pigott T, Noyes J, Umscheid CA, et al. AHRQ series on complex intervention systematic reviews—paper 5: advanced analytic methods. *Journal of Clinical Epidemiology*. 2017;90:37–42.
19. Guise JM, Butler ME, Chang C, et al. AHRQ series on complex intervention systematic reviews—paper 6: PRISMA-CI extension statement and checklist. *Journal of Clinical Epidemiology*. 2017;90:43–50.
20. Guise JM, Butler M, Chang C, et al. AHRQ series on complex intervention systematic reviews—paper 7: PRISMA-CI elaboration and explanation. *Journal of Clinical Epidemiology*. 2017;90:51–58.
21. Petticrew M. When are complex interventions “complex”? When are simple interventions “simple”? *The European Journal of Public Health*. 2011;18;21(4):397–8.
22. Anderson LM, Petticrew M, Rehfuss E, et al. Using logic models to capture complexity in systematic reviews. *Research Synthesis Methods*. 2011;2(1):33–42.
23. Kneale D, Thomas J, Harris K. Developing and Optimising the Use of Logic Models in Systematic Reviews: Exploring Practice and Good Practice in the Use of Programme Theory in Reviews. Braitstein P, editor. *PLOS ONE*. 2015;17;10(11):e0142187. doi: 10.1371/journal.pone.0142187
24. Mathematica. The Logic Model: The Foundation to Implement, Study, and Refine Patient-Centered Medical Home Models (Issue Brief) [online]. 2014. Available from: <https://www.mathematica.org/publications/the-logic-model-the-foundation-to-implement-study-and-refine-patientcentered-medical-home-models-issue-brief> (accessed 11th September 2023)
25. Rohwer A, Pfadenhauer L, Burns J, et al. Series: Clinical Epidemiology in South Africa. Paper 3: Logic models help make sense of complexity in systematic reviews and health technology assessments. *Journal of Clinical Epidemiology*. 2017;83:37–47.
26. Rehfuss EA, Booth A, Brereton L, et al. Towards a taxonomy of logic models in systematic reviews and health technology assessments: A priori, staged, and iterative approaches. *Research Synthesis Methods*. 2017; 25;9(1):13–24.

27. Pfadenhauer LM, Gerhardus A, Mozygemba K, et al. Making sense of complexity in context and implementation: the Context and Implementation of Complex Interventions (CICI) framework. *Implementation Science*. 2017; 15;12(1). doi: 10.1186/s13012-017-0552-5
28. Lewin S, Hendry M, Chandler J, et al. Assessing the complexity of interventions within systematic reviews: development, content and use of a new tool (iCAT\_SR). *BMC Medical Research Methodology*. 2017;26;17(1). doi: 10.1186/s12874-017-0349-x
29. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. *Systematic Reviews*. 2016;5(1). doi: 10.1186/s13643-016-0384-4
30. Gough D. Weight of Evidence: a framework for the appraisal of the quality and relevance of evidence. *Research Papers in Education*. 2007;22(2):213–28.
31. Popay J, Roberts H, Sowden A, et al. Guidance on the Conduct of Narrative Synthesis in Systematic Reviews A Product from the ESRC Methods Programme [online]. 2006. Available from: <https://www.lancaster.ac.uk/media/lancaster-university/content-assets/documents/fhm/dhr/chir/NSsynthesisguidanceVersion1-April2006.pdf> (accessed 11th September 2023)